These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15262744)

  • 1. Barbiturate withdrawal following Internet purchase of Fioricet.
    Romero CE; Baron JD; Knox AP; Hinchey JA; Ropper AH
    Arch Neurol; 2004 Jul; 61(7):1111-2. PubMed ID: 15262744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Barbiturate withdrawal syndrome: a case associated with the abuse of a headache medication].
    Sarrecchia C; Sordillo P; Conte G; Rocchi G
    Ann Ital Med Int; 1998; 13(4):237-9. PubMed ID: 10349206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of the barbiturate abstinence syndrome.
    Sullivan JT; Sellers EM
    Med J Aust; 1986 Nov; 145(9):456-8. PubMed ID: 3773832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal hyperthermia following haloperidol therapy of sedative-hypnotic withdrawal.
    Greenblatt DJ; Gross PL; Harris J; Shader RI; Ciraulo DA
    J Clin Psychiatry; 1978 Aug; 39(8):673-5. PubMed ID: 681307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral phenobarbital loading: a safe method of barbiturate and nonbarbiturate hypnosedative withdrawal.
    Janecek E; Kapur BM; Devenyi P
    CMAJ; 1987 Sep; 137(5):410-2. PubMed ID: 3621099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Canadian Pharmacists Association.
    McLean W; Boucher EA; Brennan M; Holbrook A; Orser R; Peachey J; Sellers E
    Can J Clin Pharmacol; 2000; 7(4):191-7. PubMed ID: 11118965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acute liver failure following tetrabamate].
    Binder D; Jost R; Flury R; Salomon F
    Schweiz Med Wochenschr; 1995 May; 125(19):965-9. PubMed ID: 7761807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gamma-hydroxybutyrate withdrawal syndrome.
    Dyer JE; Roth B; Hyma BA
    Ann Emerg Med; 2001 Feb; 37(2):147-53. PubMed ID: 11174231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentobarbital for severe gamma-butyrolactone withdrawal.
    Sivilotti ML; Burns MJ; Aaron CK; Greenberg MJ
    Ann Emerg Med; 2001 Dec; 38(6):660-5. PubMed ID: 11719746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epileptic seizure during aspirin and caffeine withdrawal in a drug induced headache.
    Antonaci F; Sances G; Manni R; Buzzi MG
    Funct Neurol; 1996; 11(6):333-7. PubMed ID: 9074914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychotropic discontinuation symptoms: a case of withdrawal neuroleptic malignant syndrome.
    Stonecipher A; Galang R; Black J
    Gen Hosp Psychiatry; 2006; 28(6):541-3. PubMed ID: 17088172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences of prolonged caffeine administration and its withdrawal on pilocarpine- and kainate-induced seizures in rats.
    Hoexter MQ; Rosa PS; Tufik S; Mello LE
    Epilepsia; 2005 Sep; 46(9):1401-6. PubMed ID: 16146434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of repeated doses of caffeine on performance and alertness: new data and secondary analyses.
    Hewlett P; Smith A
    Hum Psychopharmacol; 2007 Aug; 22(6):339-50. PubMed ID: 17514640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenobarbital treatment in a patient with resistant alcohol withdrawal syndrome.
    Hayner CE; Wuestefeld NL; Bolton PJ
    Pharmacotherapy; 2009 Jul; 29(7):875-8. PubMed ID: 19558262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychostimulant and other effects of caffeine in 9- to 11-year-old children.
    Heatherley SV; Hancock KM; Rogers PJ
    J Child Psychol Psychiatry; 2006 Feb; 47(2):135-42. PubMed ID: 16423144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management and treatment of gamma butyrolactone withdrawal syndrome: a case report and review.
    Ghio L; Cervetti A; Respino M; Belvederi Murri M; Amore M
    J Psychiatr Pract; 2014 Jul; 20(4):294-300. PubMed ID: 25036586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EEG changes in the withdrawal phase of tranquilizer or drug abuse].
    Logar C; Grabmair W; Reinbacher N; Ladurner G
    EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb; 1986 Mar; 17(1):37-40. PubMed ID: 3084203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term prognosis of analgesics abuse headache].
    Takase Y; Kishigami H; Nakano M; Tatsumi C
    Rinsho Shinkeigaku; 2005 Sep; 45(9):629-33. PubMed ID: 16248393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of γ-butyrolactone associated with severe withdrawal delirium and acute renal failure.
    Bhattacharya IS; Watson F; Bruce M
    Eur Addict Res; 2011; 17(4):169-71. PubMed ID: 21454980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Severe Fioricet Withdrawal Presenting During Admission to an Inpatient Psychiatric Unit.
    Rodulfo A; Augsten A; Wainwright E; Abramovici G
    Case Rep Psychiatry; 2021; 2021():6371953. PubMed ID: 34790421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.